RTN4 and Parkinson disease: A classic model of the pathophysiology of PD (DeLong 1990) proposes that there is an imbalance between the Go and NoGo pathway, and that dopaminergic medication exerts its therapeutic effects by enhancing Go activity but reducing NoGo activity.